Trastuzumab Deruxtecan in Patients With Solid Tumours Harbouring Specific Activating HER2 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Lancet Oncol 2024 May 03;[EPub Ahead of Print], BT Li, F Meric-Bernstam, A Bardia, Y Naito, S Siena, P Aftimos, I Anderson, G Curigliano, M de Miguel, M Kalra, DY Oh, JO Park, S Postel-Vinay, SY Rha, T Satoh, I Spanggaard, F Michelini, A Smith, KK Machado, C SauraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.